eISSN: 2081-2841
ISSN: 1689-832X
Journal of Contemporary Brachytherapy
Current Issue Archive Supplements Articles in Press Journal Information Aims and Scope Editorial Office Editorial Board Register as Author Register as Reviewer Instructions for Authors Abstracting and indexing Subscription Advertising Information Links
SCImago Journal & Country Rank

Interview with Professor Janusz Skowronek
ABS 2015
vol. 10
Original paper

Efficacy and tolerance of high-dose-rate brachytherapy boost after external radiotherapy in the treatment of squamous cell carcinoma of the anal canal

Emilien Bertin, Karen Benezery, Daniel Lam Cham Kee, Eric François, Ludovic Evesque, Mathieu Gautier, Jean-Pierre Gerard, Jean-Michel Hannoun-Levi, Alexander T Falk

J Contemp Brachytherapy 2018; 10, 6: 522–531
Online publish date: 2018/12/28
View full text
Get citation
JabRef, Mendeley
Papers, Reference Manager, RefWorks, Zotero
The aim of this study was to evaluate the efficacy and toxicity of high-dose-rate brachytherapy (HDR-BT) boost in anal squamous cell carcinoma (ASCC).

Material and methods
This was a monocentric retrospective study involving patients treated by external irradiation (± chemotherapy), with HDR-BT boost, for a localized ASCC. Clinical evaluation was performed every six months. Oncological results were analyzed with: local relapse-free survival (LRFS), colostomy-free survival (CFS), metastatic-free survival (MFS), disease-free survival (DFS), and overall survival (OS). Acute and late toxicities were collected (CTCV4.0) and LENT/SOMA score was performed.

From May 2005 to January 2018, 46 patients (pts) were analyzed. The median follow-up was 61 months (10-145 months), the median age was 65 years (34-84 years), with a sex ratio M/F = 0.24. The TNM classification was as follows: T1 – 13 pts (21.7%), T2 – 34 pts (73.9%), T3 – 2 pts (4.3%), N+ – 6 pts (13.1%). External beam radiotherapy (EBRT) delivered a median dose of 45 Gy (36-50.4 Gy) in 25 fractions, and HDR-BT 12 Gy (10-18 Gy) in 3 fractions. The median overall treatment time (OTT) was 58 days (41-101 days), with a median EBRT/brachytherapy interval of 17 days (4-60 days). Oncological findings showed 5-year rates of LRFS 81.2%, MFS 88.7%, DFS 70%, and OS 90%. All abdominoperineal amputations were performed in case of local relapse (4 pts, 8.7%), leading to a 5-year CFS of 79.5%. Acute urinary toxicities were frequent (G1 41.3%, G2 4.3%). The acute digestive toxicities were: G1 71.7%, G2 6.5%, and G3 2.2%. The late urinary toxicities were: G1 4.3%, G2 2.2%, and G3 2.2%. Late digestive toxicities were: G1 56.5%, G2 8.7%, G3 2.2%, and G4 2.2%.

In ASCC management, HDR-BT boost appears to be a treatment with a long-term acceptable toxicity profile, shorter than EBRT boost, with a reduction of side effects.


anal squamous cell carcinoma, brachytherapy, boost, high-dose-rate, radiotherapy

Abramowitz L, Jacquard A-C, Jaroud F et al. Human papillomavirus genotype distribution in anal cancer in France: The EDiTH V study. Int J Cancer 2011; 129: 433-439.
Robinson D, Coupland V, Møller H. An analysis of temporal and generational trends in the incidence of anal and other HPV-related cancers in Southeast England. Br J Cancer 2009; 100: 527-531.
Nielsen A, Munk C, Kjaer SK. Trends in incidence of anal cancer and high-grade anal intraepithelial neoplasia in Denmark, 1978-2008. Int J Cancer 2012; 130: 1168-1173.
Johnson LG, Madeleine MM, Newcomer LM, et al. Anal cancer incidence and survival: The Surveillance, Epidemiology, and End Results experience, 1973-2000. Cancer 2004; 101: 281-288.
Colón-López V, Shiels MS, Machin M et al. Anal cancer risk among people with HIV infection in the United States. J Clin Oncol 2017; 36: 68-75.
Nigro ND, Vaitkevicius VK, Considine B. Combined therapy for cancer of the anal canal: a preliminary report. Dis Colon Rectum 1974; 17: 354-356.
Martin D, Balermpas P, Winkelmann R et al. Anal squamous cell carcinoma – State of the art management and future perspectives. Cancer Treat Rev 2018; 65: 11-21.
Lépinoy A, Lescut N, Puyraveau M et al. Evaluation of a 36 Gy elective node irradiation dose in anal cancer. Radiother Oncol 2015; 116: 197-201.
Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research. Lancet Lond Engl 1996; 348: 1049-1054.
Moureau-Zabotto L, Ortholan C, Hannoun-Levi J-M et al. Role of brachytherapy in the boost management of anal carcinoma with node involvement (CORS-03 Study). Int J Radiat Oncol 2013; 85: e135-142.
Glynne-Jones R, Nilsson PJ, Aschele C et al. Anal cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. Eur J Surg Oncol EJSO 2014; 40: 1165-1176.
Cordoba A, Escande A, Leroy T et al. Low-dose-rate interstitial brachytherapy boost for the treatment of anal canal cancers. Brachytherapy 2017; 16: 230-235.
Pierquin B, Dutreix A, Paine CH et al. The Paris system in interstitial radiation therapy. Acta Radiol Oncol Radiat Phys Biol 1978; 17: 33-48.
LENT SOMA scales for all anatomic sites. Int J Radiat Oncol Biol Phys 1995; 31: 1049-1091.
Lund J-Å, Kaasa S, Wibe A et al. Late radiation effects to the rectum and anus after treatment for prostate cancer; validity of the LENT/SOMA score. Acta Oncol 2013; 52: 727-735.
NCI Term Browser [https://ncit-stage.nci.nih.gov/ncitbrows­er/pages/vocabulary.jsf?dictionary=CTCAE&version=4.03, cited 10th Sep 2018].
Papillon J, Montbarbong JF, Gerard JP et al. Interstitial Curietherapie in the conservative treatment of anal and rectal cancers. Int J Radiat Oncol Biol Phys 1989; 17: 1161-1169.
Falk AT, Claren A, Benezery K et al. Interstitial high-dose rate brachytherapy as boost for anal canal cancer. Radiat Oncol 2014; 9: 240.
Gryc T, Ott O, Putz F et al. Interstitial brachytherapy as a boost to patients with anal carcinoma and poor response to chemoradiation: Single-institution long-term results. Brachytherapy 2016; 15: 865-872.
Hannoun-Levi J-M, Ortholan C, Resbeut M et al. High-dose split-course radiation therapy for anal cancer: outcome analysis regarding the boost strategy (CORS-03 Study). Int J Radiat Oncol Biol Phys 2011; 80: 712-720.
Northover J, Glynne-Jones R, Sebag-Montefiore D et al. Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I). Br J Cancer 2010; 102: 1123-1128.
Ajani JA, Winter KA, Gunderson LL et al. Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. JAMA 2008; 299: 1914-1921.
Niehoff P, Kovács G. HDR brachytherapy for anal cancer. J Gastrointest Oncol 2014; 5: 218-222.
Frakulli R, Buwenge M, Cammelli S et al. Brachytherapy boost after chemoradiation in anal cancer: a systematic review. J Contemp Brachytherapy 2018; 10: 246-253.
Oehler-Jänne C, Huguet F, Provencher S et al. HIV-specific differences in outcome of squamous cell carcinoma of the anal canal: a multicentric cohort study of HIV-positive patients receiving highly active antiretroviral therapy. J Clin Oncol 2008; 26: 2550-2557.
Das P, Crane CH, Eng C, Ajani JA. Prognostic factors for squamous cell cancer of the anal canal. Gastrointest Cancer Res 2008; 2: 10-14.
Bruna A, Gastelblum P, Thomas L et al. Treatment of squamous cell anal canal carcinoma (SCACC) with pulsed dose rate brachytherapy: A retrospective study. Radiother Oncol 2006; 79: 75-79.
Wagner JP, Mahe MA, Romestaing P et al. Radiation therapy in the conservative treatment of carcinoma of the anal canal. Int J Radiat Oncol Biol Phys 1994; 29: 17-23.
Bartelink H, Roelofsen F, Eschwege F, et al. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J Clin Oncol 1997; 15: 2040-2049.
Kapoor R, Khosla D, Shukla AK et al. Dosimetric and clinical outcome in image-based high-dose-rate interstitial brachytherapy for anal cancer. Brachytherapy 2014; 13: 388-393.
Kachnic LA, Winter K, Myerson RJ et al. RTOG 0529: A Phase 2 Evaluation of Dose-Painted Intensity Modulated Radiation Therapy in Combination With 5-Fluorouracil and Mitomycin-C for the Reduction of Acute Morbidity in Carcinoma of the Anal Canal. Int J Radiat Oncol 2013; 86: 27-33.
Deniaud-Alexandre E, Touboul E, Tiret E et al. Epidermoid carcinomas of anal canal treated with radiation therapy and concomitant chemotherapy (5-fluorouracil and cisplatin). Cancer/Radiothérapie 2006; 10: 572-582.
Tagliaferri L, Manfrida S, Barbaro B et al. MITHRA – multiparametric MR/CT image adapted brachytherapy (MR/CT-IABT) in anal canal cancer: a feasibility study. J Contemp Brachytherapy 2015; 7: 336-345.
Quick links
© 2019 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe